What Clasid Treats: Main Uses and Benefits

This medicine is commonly used to help manage a variety of infections caused by susceptible bacteria, which helps address symptom clusters that create noticeable physiological strain.

Primary Treatment for Acute Bacterial Infections

Clasid is applied across domains where additional symptomatic support is needed to address bacterial pathogens responsible for infections of the upper and lower respiratory tract. This includes conditions like community-acquired pneumonia, acute exacerbations of chronic bronchitis, sinusitis, and bacterial pharyngitis, along with uncomplicated skin and soft tissue infections. The medicine contributes to easing the overall symptom load by managing acute manifestations such as high fever, persistent cough, and localized swelling, supporting the patient during difficult episodes.

Specialized Therapy for Persistent Pathogens and Allergic Patients

The medication is commonly used across conditions characterized by periods of heightened symptoms, such as chronic duodenal ulcers linked to Helicobacter pylori infection, where it is an established part of combination eradication therapy. It is also used for managing and preventing Mycobacterium Avium Complex (MAC) infection, particularly in immunocompromised individuals. Furthermore, Clasid supports patients who cannot use first-line agents due to a penicillin allergy, and may be part of symptomatic management in allergic patients, offering an effective alternative for common infections, including in pediatric patients (e.g., acute otitis media).

Quick Fact: Relief for Respiratory Discomfort
Symptom focus	Persistent cough, chest discomfort, and fever associated with acute bacterial respiratory infections.
Key benefit	Provides supportive management, assisting with maintaining functional stability during symptomatic periods.

Regulatory References

1. NIH MedlinePlus Drug Information overview on Clarithromycin

Who Can and Cannot Use Clasid (Clarithromycin)

Official regulatory documents define strict population-based constraints for the use of Clasid, which contains the macrolide antibiotic Clarithromycin.

Contraindicated Populations (Must Not Use)

Clasid is contraindicated for individuals with a known hypersensitivity to any macrolide antibiotic or excipient, and for patients with a history of cholestatic jaundice or hepatic dysfunction caused by previous clarithromycin use.

The medicine is also prohibited for patients with a history of QT prolongation, ventricular cardiac arrhythmias, or uncorrected hypokalemia/hypomagnesemia. Use is absolutely contraindicated in patients with severe hepatic failure combined with renal impairment.

Age and Physiological Status Rules

Population Group	Regulatory Eligibility Status
Infants (< 6 months)	Safety and efficacy are not established for most infections.
Children (Under 12 years)	Film-coated tablets are not recommended; the oral suspension is appropriate.
Pregnancy	Not recommended, especially during the first trimester, unless no alternative therapy is appropriate.
Breastfeeding	Not generally recommended due to excretion into breast milk.

Condition-Based Restrictions

Patients with moderate to severe renal impairment (CrCl < 30 mL/min) require conditional use and reduced dosing. Furthermore, Clasid is contraindicated if co-administered with certain drugs, including Lovastatin, Simvastatin, Colchicine (in renal/hepatic impairment), and Ergotamine/Dihydroergotamine.

Interactions with other medicines and products

Clasid (Clarithromycin) is officially documented as a strong irreversible inhibitor of the CYP3A4 enzyme system, which significantly reduces the clearance of many co-administered medicinal products. This interaction mechanism is the basis for several regulatory restrictions.

Formal Contraindications

Co-administration with Clasid is strictly prohibited with the following medicines due to the risk of severe adverse outcomes:

Classification	Examples of Prohibited Medicines
Cardiac Arrhythmia Risk	Pimozide, Astemizole, Cisapride, Terfenadine
Myopathy Risk	Lovastatin, Simvastatin (must be suspended)
Acute Toxicity Risk	Ergotamine, Dihydroergotamine

Clinically Significant Interactions

Clasid increases the systemic exposure of drugs like Digoxin, Tacrolimus, Theophylline, and Sildenafil. This requires careful monitoring and potential adjustment by a healthcare provider, according to regulatory labeling. Co-administration with Oral Anticoagulants (e.g., Warfarin) also presents a documented risk of serious bleeding events due to potentiation of effects.

Population and Timing Restrictions

Use is contraindicated with Colchicine in patients with pre-existing renal or hepatic impairment. Furthermore, the use of Clasid is prohibited in patients with pre-existing hypokalaemia or hypomagnesaemia due to an elevated risk of cardiac events.

Clasid (Clarithromycin) initiates its effect by binding specifically to the 23S rRNA component of the bacterial 50S ribosomal subunit.

This molecular interaction physically blocks the peptide exit tunnel, which halts the elongation of peptide chains. The resulting arrest of protein synthesis shifts the bacterial state to bacteriostasis, limiting the ability of the pathogen population to increase. This physiological change facilitates clearance of the arrested pathogen population by the host's immune mechanisms.

Beyond direct inhibition, Clarithromycin exhibits active intracellular accumulation, allowing it to be transported and concentrated within host phagocytes to efficiently target pathogens residing inside them. Furthermore, its active metabolite, 14-hydroxy-clarithromycin, works synergistically with the parent compound, sharing the same ribosomal mechanism for sustained suppression of bacterial growth. The mechanism is constrained by bacterial counter-defenses, including ribosomal mutations or the action of methylase enzymes, and by efflux pumps that actively expel the molecule, leading to the functional failure of the bacteriostatic effect.

Clasid, which contains clarithromycin, is administered either orally (as a tablet, extended-release tablet, or suspension) or via intravenous (IV) infusion. The choice of route is determined by the patient's condition, with the IV route typically limited to 2 to 5 days before a mandatory switch to the oral form.

Administration Parameter	Administration Overview
Oral Dosing (Adult)	Immediate-release forms are typically taken as 250 mg or 500 mg twice daily (BID). Extended-release forms are taken as 1000 mg once daily (QD).
Frequency Pattern	BID for immediate-release and IV; QD for extended-release. Course duration is commonly 7 to 14 days.
Timing & Food	Immediate-release forms can be taken without regard to meals. Extended-release tablets must be taken with food.
Special Constraints	Extended-release tablets must be swallowed whole; they must not be crushed, broken, or chewed. The IV formulation must be given over 60 minutes and cannot be administered as a bolus or intramuscular injection.

For specific populations, specific guidelines apply for required modifications. In patients with severe renal impairment (creatinine clearance < 30 mL/min), the total daily dose must be reduced by half. Pediatric dosing utilizes the oral suspension and is calculated based on weight, typically 7.5 mg/kg every 12 hours. If a dose is missed, the dose should be taken as soon as remembered unless it is close to the next scheduled dose, in which case the missed dose is skipped to prevent doubling the amount.

Research Evidence / Overview of Studies for Clasid

---

Evidence for Acute Respiratory and Skin Infections

Research has examined Clasid (Clarithromycin) in short-term Randomized Controlled Trials (RCTs). The drug was studied for outcomes related to systemic or functional imbalance that were evaluated in common bacterial infections, such as pneumonia, acute exacerbations of chronic bronchitis, and uncomplicated skin infections. These studies involved large groups of immunocompetent adults and children, tracking their progress in both outpatient and hospitalized settings.

The trials were primarily used in research exploring how symptoms change over time. Outcomes measured included the measurement of change in key outcomes related to physical discomfort, such as fever and cough, and the status of the specific bacteria after treatment (bacteriological eradication). Studies report how symptoms evolved in the observed populations over the defined time intervals.

---

Research in Specialized and Complex Infections

Research has also explored the role of Clasid in more specialized and chronic conditions, where it is used as one component within a combination regimen.

For Helicobacter pylori infection, which is associated with chronic duodenal ulcers, RCTs was evaluated in adults receiving multi-drug treatments. These studies was studied for their evaluation of eradication success, confirmed by specific diagnostic tests conducted after therapy completion. Findings were mixed across different regions. This is because evidence quality varies across studies, and the prevalence of Clarithromycin resistance was observed in some studies to influence findings in some parts of the world.

For managing and preventing Mycobacterium Avium Complex (MAC) infection, particularly in immunocompromised individuals, research primarily consists of long-term cohort studies and supporting trials. These studies monitored outcomes related to systemic or functional imbalance over extended time intervals (months to years).

---

Long-Term Follow-up and Extended Observational Data

Beyond the immediate evaluation of acute infections, large-scale, long-term observational research has examined patient health for years after they received a short course of Clasid. Specifically, this research was studied for long-term all-cause mortality and the incidence of major heart-related events in specific patient groups.

Data show patterns related to long-term mortality was observed in some studies in high-risk patient subgroups. However, findings were mixed when compared to subsequent large-scale population studies. This means that subgroup findings are uncertain when generalizing to the wider population, and the long-term effects are not fully established outside of the specific high-risk groups that were the focus of the primary study.

Key Studies & References

1. Clinical experience with clarithromycin for the treatment of respiratory tract infections
2. Disseminated Mycobacterium avium Complex: Adult and Adolescent OIs | NIH - Clinical Info .HIV.gov (Guidelines)

Common questions about Clasid (FAQ)

---

Q: What specific kinds of bacterial infections is Clasid used to treat?

Clasid (clarithromycin) is officially indicated for treating specific bacterial infections in several areas of the body, including the respiratory tract and skin/soft tissue. It is also used as part of a combination therapy to treat H. pylori infection, which is linked to ulcers, and to prevent or treat Mycobacterium avium complex (MAC) infection in certain individuals. Official regulatory documents list these uses in the drug's approved indications.

---

Q: How quickly should a patient expect Clasid to start showing an effect on an infection?

Official patient guidance indicates that a person may generally start feeling some improvement in their condition within a few days of beginning treatment with Clasid. However, the time it takes to notice an effect can vary based on the type and severity of the infection being treated. Regulatory information emphasizes the need to continue the full prescribed course.

---

Q: What are the general risks described in official documents if an antibiotic like Clasid is stopped too soon?

Regulatory documents contain information emphasizing that the full prescribed course should be completed by a patient. Stopping the antibiotic before the course is finished may not fully clear the infection, allowing the remaining bacteria to multiply. This premature discontinuation can also contribute to the development of antibiotic resistance.

---

Q: What are the official guidelines regarding consuming alcohol while taking Clasid?

Some official health authorities provide guidance stating that consuming alcohol is generally permitted while a patient is taking clarithromycin (Clasid). Guidance on individual alcohol consumption should be addressed by a healthcare professional.

---

Q: Does Clasid interact with common over-the-counter pain or fever medications?

While specific contraindications often focus on prescription drugs, official advice contains statements recommending that consultation with a healthcare provider take place before combining Clasid with any over-the-counter pain relievers, fever medications, or other non-prescription remedies. This precaution is advised because of the potential for unidentified interactions or interference with the metabolism of the antibiotic.

---

Q: Can Clasid cause feelings of dizziness, confusion, or disorientation?

Yes, the official product information for Clasid lists dizziness and vertigo as possible side effects, and some reports include feelings of confusion or disorientation. Due to these potential effects, the drug's safety information describes possible temporary impairment of the ability to drive or operate machinery.

---

Q: Is it normal to see part of the Clasid tablet or capsule in the stool?

For patients taking the extended-release tablet form of Clasid, regulatory information confirms that it is normal to see the tablet shell or remnant pass through the stool. This phenomenon is expected because the medication's active ingredient has already been absorbed by the body, and the remaining shell is inactive.

---

Q: Does taking Clasid require specific monitoring like routine blood tests?

Routine blood monitoring is not specified for all patients taking Clasid. However, official labeling lists several laboratory parameters (such as elevated liver enzymes and blood urea) that have been monitored in studies. The need for specific blood tests is determined by individual health circumstances and requires discussion with a healthcare provider.

---

Q: What are the official recommendations regarding specific herbal supplements or vitamins and Clasid?

Regulatory sources contain strong statements advising that consultation with a healthcare professional take place before combining Clasid with herbal supplements or high-dose vitamins. This is a safety precaution due to the potential for interactions with the medication’s metabolism, especially because the drug is known to affect the CYP3A4 enzyme system.

---

Q: If the color or shape of the Clasid pill changes with a refill, does that mean it’s a different medicine?

No, a change in the color or shape of the pill usually does not mean the active medicine is different. Clasid and its generic form, clarithromycin, contain the exact same active ingredient. These visual differences occur because different manufacturers may use various inactive ingredients (like binders or colorants) when producing generic versions.

---

Q: What is the documented effect of Clasid on pre-existing conditions like myasthenia gravis?

Official regulatory information indicates that the use of Clasid in patients with myasthenia gravis (a chronic muscle-weakening disease) requires caution. Reports suggest that clarithromycin has the potential to worsen the symptoms of this pre-existing condition.

---

Q: What general information is available about the expiration and potency of the drug Clasid?

The general stability and potency information for Clasid is based on its preparation. Official information describes that tablets are to be stored at room temperature, protected from light, and kept in the original container. The reconstituted liquid suspension, according to official information, must be discarded after 14 days, even if there is medicine remaining.

---

Q: Why is Clasid sometimes mentioned in discussions about ear infections (otitis media)?

Clasid (clarithromycin) is a broad-spectrum antibiotic and is commonly mentioned in relation to ear infections, such as acute otitis media, when they are caused by susceptible bacteria. Official prescribing information includes specific guidelines for its use in children with this type of infection.

---

Q: What information is available regarding a potential interaction between Clasid and hormonal contraceptives?

Official documents indicate that clarithromycin may have a possible effect on the blood levels of certain components of hormonal contraceptives. Furthermore, if the medication causes side effects like severe diarrhea or vomiting, the absorption and effectiveness of an oral contraceptive pill may be reduced.

---

Q: Is unusual tiredness or fatigue listed as a common side effect of Clasid treatment?

Yes, official regulatory labeling reports that unusual tiredness or fatigue (clinically known as asthenia) has been documented as a possible adverse event during clinical trials of clarithromycin.

---

Q: Is there a risk of tooth or tongue discoloration associated with the use of Clasid?

Yes, the official regulatory safety information for Clasid includes reports of discoloration of the tongue and teeth as a side effect. The reported discoloration is generally reversible, with resolution occurring after treatment completion or through professional dental cleaning.

---

Q: Does official information note any potential worsening of diabetic control when using Clasid?

Official prescribing information notes a potential for interaction when Clasid is used alongside medications for diabetes, such as insulin or certain oral hypoglycemics. This combination has occasionally been associated with a risk of hypoglycemia (low blood sugar), which official documents indicate requires careful monitoring.

Official Storage and Disposal Requirements

Official regulatory documents define specific conditions for storing Clasid (clarithromycin), which vary by product form, and provide clear rules for disposal.

Product Form	Storage Conditions	Stability/In-Use Rule
Film-Coated Tablets	Store at room temperature (68 F to 77 F or 20 C to 25 C). Must be protected from light.	Keep in original, tightly closed container.
Oral Suspension (Reconstituted)	Store at 59 F to 86 F (15 C to 30 C). Do not refrigerate.	Must be discarded after 14 days from mixing.

All forms of the medicine must be kept out of the sight and reach of children.

For disposal of unused or expired product, the official guidance recommends using a drug take-back program. If a take-back option is unavailable, the medicine should be mixed with an undesirable substance (such as dirt or coffee grounds), sealed in a container, and placed in the household trash. The product must not be flushed down a toilet.